Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,505 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Scalable, Micro-Neutralization Assay for Qualitative Assessment of SARS-CoV-2 (COVID-19) Virus-Neutralizing Antibodies in Human Clinical Samples.
Bennett RS, Postnikova EN, Liang J, Gross R, Mazur S, Dixit S, Lukin VV, Kocher G, Yu S, Georgia-Clark S, Gerhardt D, Cai Y, Marron L, Holbrook MR. Bennett RS, et al. Among authors: dixit s. bioRxiv [Preprint]. 2021 Mar 5:2021.03.05.434152. doi: 10.1101/2021.03.05.434152. bioRxiv. 2021. Update in: Viruses. 2021 May 12;13(5):893. doi: 10.3390/v13050893. PMID: 33688658 Free PMC article. Updated. Preprint.
Broadly neutralizing antibodies target the coronavirus fusion peptide.
Dacon C, Tucker C, Peng L, Lee CD, Lin TH, Yuan M, Cong Y, Wang L, Purser L, Williams JK, Pyo CW, Kosik I, Hu Z, Zhao M, Mohan D, Cooper A, Peterson M, Skinner J, Dixit S, Kollins E, Huzella L, Perry D, Byrum R, Lembirik S, Zhang Y, Yang ES, Chen M, Leung K, Weinberg RS, Pegu A, Geraghty DE, Davidson E, Douagi I, Moir S, Yewdell JW, Schmaljohn C, Crompton PD, Holbrook MR, Nemazee D, Mascola JR, Wilson IA, Tan J. Dacon C, et al. Among authors: dixit s. bioRxiv [Preprint]. 2022 Apr 12:2022.04.11.487879. doi: 10.1101/2022.04.11.487879. bioRxiv. 2022. Update in: Science. 2022 Aug 12;377(6607):728-735. doi: 10.1126/science.abq3773. PMID: 35441178 Free PMC article. Updated. Preprint.
Broadly neutralizing antibodies target the coronavirus fusion peptide.
Dacon C, Tucker C, Peng L, Lee CD, Lin TH, Yuan M, Cong Y, Wang L, Purser L, Williams JK, Pyo CW, Kosik I, Hu Z, Zhao M, Mohan D, Cooper AJR, Peterson M, Skinner J, Dixit S, Kollins E, Huzella L, Perry D, Byrum R, Lembirik S, Drawbaugh D, Eaton B, Zhang Y, Yang ES, Chen M, Leung K, Weinberg RS, Pegu A, Geraghty DE, Davidson E, Douagi I, Moir S, Yewdell JW, Schmaljohn C, Crompton PD, Holbrook MR, Nemazee D, Mascola JR, Wilson IA, Tan J. Dacon C, et al. Among authors: dixit s. Science. 2022 Aug 12;377(6607):728-735. doi: 10.1126/science.abq3773. Epub 2022 Jul 12. Science. 2022. PMID: 35857439 Free PMC article.
Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses.
Dacon C, Peng L, Lin TH, Tucker C, Lee CD, Cong Y, Wang L, Purser L, Cooper AJR, Williams JK, Pyo CW, Yuan M, Kosik I, Hu Z, Zhao M, Mohan D, Peterson M, Skinner J, Dixit S, Kollins E, Huzella L, Perry D, Byrum R, Lembirik S, Murphy M, Zhang Y, Yang ES, Chen M, Leung K, Weinberg RS, Pegu A, Geraghty DE, Davidson E, Doranz BJ, Douagi I, Moir S, Yewdell JW, Schmaljohn C, Crompton PD, Mascola JR, Holbrook MR, Nemazee D, Wilson IA, Tan J. Dacon C, et al. Among authors: dixit s. Cell Host Microbe. 2023 Jan 11;31(1):97-111.e12. doi: 10.1016/j.chom.2022.10.010. Epub 2022 Nov 7. Cell Host Microbe. 2023. PMID: 36347257 Free PMC article.
Randomized Trial of Vaccines for Zaire Ebola Virus Disease.
PREVAC Study Team; Kieh M, Richert L, Beavogui AH, Grund B, Leigh B, D'Ortenzio E, Doumbia S, Lhomme E, Sow S, Vatrinet R, Roy C, Kennedy SB, Faye S, Lees S, Millimouno NP, Camara AM, Samai M, Deen GF, Doumbia M, Espérou H, Pierson J, Watson-Jones D, Diallo A, Wentworth D, McLean C, Simon J, Wiedemann A, Dighero-Kemp B, Hensley L, Lane HC, Levy Y, Piot P, Greenwood B, Chêne G, Neaton J, Yazdanpanah Y. PREVAC Study Team, et al. N Engl J Med. 2022 Dec 29;387(26):2411-2424. doi: 10.1056/NEJMoa2200072. Epub 2022 Dec 14. N Engl J Med. 2022. PMID: 36516078 Clinical Trial.
Multivalent viral particles elicit safe and efficient immunoprotection against Nipah Hendra and Ebola viruses.
Ithinji DG, Buchholz DW, Ezzatpour S, Monreal IA, Cong Y, Sahler J, Bangar AS, Imbiakha B, Upadhye V, Liang J, Ma A, Bradel-Tretheway B, Kaza B, Yeo YY, Choi EJ, Johnston GP, Huzella L, Kollins E, Dixit S, Yu S, Postnikova E, Ortega V, August A, Holbrook MR, Aguilar HC. Ithinji DG, et al. Among authors: dixit s. NPJ Vaccines. 2022 Dec 17;7(1):166. doi: 10.1038/s41541-022-00588-5. NPJ Vaccines. 2022. PMID: 36528644 Free PMC article.
Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamsters.
Cong Y, Mucker EM, Perry DL, Dixit S, Kollins E, Byrum R, Huzella L, Kim R, Josleyn M, Kwilas S, Stefan C, Shoemaker CJ, Koehler J, Coyne S, Delp K, Liang J, Drawbaugh D, Hischak A, Hart R, Postnikova E, Vaughan N, Asher J, St Claire M, Hanson J, Schmaljohn C, Eakin AE, Hooper JW, Holbrook MR. Cong Y, et al. Among authors: dixit s. Antiviral Res. 2023 May;213:105589. doi: 10.1016/j.antiviral.2023.105589. Epub 2023 Mar 30. Antiviral Res. 2023. PMID: 37003305 Free PMC article.
Longitudinal analyses using 18F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models.
Cong Y, Lee JH, Perry DL, Cooper K, Wang H, Dixit S, Liu DX, Feuerstein IM, Solomon J, Bartos C, Seidel J, Hammoud DA, Adams R, Anthony SM, Liang J, Schuko N, Li R, Liu Y, Wang Z, Tarbet EB, Hischak AMW, Hart R, Isic N, Burdette T, Drawbaugh D, Huzella LM, Byrum R, Ragland D, St Claire MC, Wada J, Kurtz JR, Hensley LE, Schmaljohn CS, Holbrook MR, Johnson RF. Cong Y, et al. Among authors: dixit s. Antiviral Res. 2023 Jun;214:105605. doi: 10.1016/j.antiviral.2023.105605. Epub 2023 Apr 15. Antiviral Res. 2023. PMID: 37068595 Free PMC article.
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
Lee AW, Liu K, Lhomme E, Blie J, McCullough J, Onorato MT, Connor L, Simon JK, Dubey S, VanRheenen S, Deutsch J, Owens A, Morgan A, Welebob C, Hyatt D, Nair S, Hamzé B, Guindo O, Sow SO, Beavogui AH, Leigh B, Samai M, Akoo P, Serry-Bangura A, Fleck S, Secka F, Lowe B, Watson-Jones D, Roy C, Hensley LE, Kieh M, Coller BG; PREVAC Study Team. Lee AW, et al. Clin Infect Dis. 2024 Apr 10;78(4):870-879. doi: 10.1093/cid/ciad693. Clin Infect Dis. 2024. PMID: 37967326 Free PMC article. Clinical Trial.
1,505 results